Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
Grace QianXiaosong WangNaomi J PatelYumeko KawanoXiaoqing FuClaire E CookKathleen M M VanniEmily N KowalskiEmily P BanasiakKatarina J BadeShruthi SrivatsanZachary K WilliamsDerrick J ToddMichael E WeinblattZachary S WallaceJeffrey A SparksPublished in: medRxiv : the preprint server for health sciences (2022)
These results should encourage clinicians to prescribe and SARD patients to seek prompt outpatient COVID-19 treatment.This research provides an early estimate of the prevalence of COVID-19 rebound after oral outpatient treatment to quantify this risk to clinicians and SARD patients and encourage future research.
Keyphrases
- sars cov
- end stage renal disease
- coronavirus disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- palliative care
- peritoneal dialysis
- type diabetes
- skeletal muscle
- risk factors
- combination therapy
- adipose tissue
- patient reported outcomes
- current status
- replacement therapy
- insulin resistance
- drug induced
- smoking cessation